ProfileGDS5678 / 1460056_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 69% 74% 71% 68% 41% 69% 69% 62% 79% 82% 77% 78% 77% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.5322572
GSM967853U87-EV human glioblastoma xenograft - Control 24.2678569
GSM967854U87-EV human glioblastoma xenograft - Control 34.7812574
GSM967855U87-EV human glioblastoma xenograft - Control 44.5141371
GSM967856U87-EV human glioblastoma xenograft - Control 54.1716268
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.031141
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.2598669
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2557269
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7209662
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.5397579
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.9200582
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.3456877
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.2918878
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.2065177